Managing bleeds on anticoagulant therapy
Bleeding remains the most significant and frequent complication of oral anticoagulant (OAC) therapy, impacting morbidity, mortality, and the risk of thromboembolic events if anticoagulation is interrupted.
While direct oral anticoagulants (DOACs) offer superior safety against intracranial bleeding compared to vitamin K antagonists (VKAs), they may present an increased risk of gastrointestinal bleeding. The use of combination antithrombotic therapy (e.g., OAC plus antiplatelet agents) heightens the bleeding risk, highlighting the need for individualized patient and regimen selection, along with regular reassessment using validated bleeding risk scores such as HAS-BLED and PRECISE-HBR. It is crucial to avoid unnecessary triple therapy, manage drug interactions, and implement routine gastroprotection for high-risk patients.
Hemodynamic instability or involvement of critical anatomical sites (e.g., intracranial, gastrointestinal) necessitates urgent stabilization, discontinuation of antithrombotics, targeted resuscitation, and, when indicated, anticoagulant reversal using drug-specific antidotes (idarucizumab for dabigatran, andexanet alfa or PCC for FXa inhibitors, vitamin K + PCC for VKAs).
Early intervention with multidisciplinary involvement enhances outcomes. Restarting OAC after major bleeding should be prioritized once hemostasis and source control are achieved, balancing the patient-specific thrombotic versus bleeding risk, and considering dose reduction or agent change where appropriate.
Minor bleeding is common but rarely requires hospitalization or cessation of therapy. Management is primarily supportive, focusing on local measures, correction of reversible risk factors, and avoiding unnecessary OAC interruption.